141 results on '"Hemmer B"'
Search Results
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Dimethylfumarate
3. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
4. Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders
5. S2k-Leitlinie: Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen
6. Diagnosis and Management of Neuromyelitis Optica
7. Disease-Specific Cerebrospinal Fluid Investigations
8. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients
9. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
10. Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis
11. Treatment of MOG antibody associated disorders: results of an international survey
12. T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis
13. Molecular mimicry and multiple sclerosis — a possible role for degenerate T cell recognition in the induction of autoimmune responses
14. The affinity spectrum of myelin basic protein-reactive T cells
15. From specificity to degeneracy to molecular mimicry: antigen recognition of human autoreactive and pathogen-specific CD4+ T cells
16. Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis
17. ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis
18. Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients
19. The spectrum of aseptic central nervous system infections in southern Germany - demographic, clinical and laboratory findings
20. Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity
21. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie
22. Fampridin ist ein therapeutischer Fortschritt – Pro
23. Aktuelles zur Therapieumstellung bei Multipler Sklerose
24. Oxygen Transport to the Exercising Muscle
25. Complex antibody profiling to predict clinical outcome in childhood ADS
26. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis
27. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders
28. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
29. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease
30. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases
31. Benefit 11: Long-term follow-up study of patients with clinically isolated syndrome treated with interferon beta-1b
32. Übersicht und Analyse internationaler Fall-Kontroll-Studien zu „Chronischen zerebrospinalen venösen Insuffizienz“ (CCSVI) und Multipler Sklerose
33. Hunting for autoantibodies in multiple sclerosis
34. Inward rectifying potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease
35. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”
36. Crowned-Dens-Syndrom
37. Neuromyelitis optica following human papillomavirus vaccination
38. Interferon β-1b in Klinik und Praxis
39. Genetic Determinants of IgG Synthesis in the Cerebrospinal Fluid of Patients with Multiple Sclerosis (S20.006)
40. BAF312, a Selective Sphingosine-1-Phosphate Receptor Modulator Improves MRI and Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (RRMS) (S30.001)
41. Glatiramer Acetate Complements Anti-CD20-Mediated B-Cell Depletion in Treatment of CNS Autoimmune Disease (P04.124)
42. Is Systemic Thrombolysis Justified in Patients with Ischemic Stroke and Recent Dental Extraction? (P03.009)
43. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?
44. Pearls & Oy-sters: Cerebral HSV-2 vasculitis presenting as hemorrhagic stroke followed by multifocal ischemia
45. Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
46. Diagnostik der Multiplen Sklerose 2010 Revision der McDonald-Kriterien
47. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients
48. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
49. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
50. Plasmapheresis therapy in children with inflammatory demyelinating disorders of the CNS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.